Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
LivaNova PLC is a global medical technology company focused on the development and commercialization of advanced therapies and medical devices. The company operates primarily within the medical devices and healthcare technology industries, with a focus on improving outcomes for patients with cardiovascular and neurological conditions. LivaNova’s core revenue is driven by implantable devices, capital equipment, and related disposables used in both acute hospital settings and long-term chronic disease management.
The company’s primary business lines are Cardiopulmonary and Neuromodulation, serving hospitals, clinicians, and patients across developed and select emerging markets. LivaNova is known for its strong clinical evidence base, long product lifecycles, and specialized expertise in high-acuity therapies. The company was formed in 2015 through the merger of Sorin S.p.A., an Italian cardiovascular device manufacturer, and Cyberonics, Inc., a U.S.-based neuromodulation company, creating a diversified medical technology platform with global reach.
Business Operations
LivaNova operates through two major reportable segments: Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment generates revenue through heart-lung machines, oxygenators, perfusion tubing systems, and related accessories used in cardiac surgery and extracorporeal circulation. These products are sold primarily to hospitals and cardiac centers and generate recurring revenue through consumables tied to surgical procedures.
The Neuromodulation segment is centered on the VNS Therapy® System, an implantable vagus nerve stimulation device approved for the treatment of drug-resistant epilepsy and treatment-resistant depression in certain markets. LivaNova maintains manufacturing, R&D, and commercial operations in the United States and Europe, supported by a global sales and distribution network. The company operates through multiple wholly owned subsidiaries, including LivaNova USA, Inc. and Sorin Group Italia S.r.l., and relies primarily on direct sales rather than joint ventures for its core products.
Strategic Position & Investments
LivaNova’s strategic direction emphasizes focused investment in high-margin, clinically differentiated therapies with strong intellectual property protection. The company prioritizes organic growth through product innovation, clinical research, and lifecycle management of existing platforms, particularly within neuromodulation and cardiopulmonary bypass technologies. Management has publicly articulated a strategy of disciplined capital allocation, including selective divestitures and portfolio simplification to concentrate on core franchises.
Historically, LivaNova has pursued targeted acquisitions to expand its technology base, including the acquisition of Cyberonics, Inc. through the 2015 merger and subsequent smaller technology-focused transactions. The company has also invested in emerging neuromodulation applications beyond epilepsy, though some investigational programs have been discontinued or deprioritized; data inconclusive based on available public sources regarding current commercial expansion beyond core indications.
Geographic Footprint
LivaNova is headquartered in London, United Kingdom, with significant operational and commercial presence in North America and Europe. The United States represents the company’s largest single market by revenue, supported by manufacturing, R&D, and corporate functions, while Italy and Germany serve as key hubs for cardiopulmonary manufacturing and engineering.
The company maintains sales and distribution capabilities across Europe, Asia-Pacific, and parts of Latin America, serving both public and private healthcare systems. While LivaNova does not have material manufacturing operations in every region it serves, its products are distributed globally, giving the company meaningful international exposure and a diversified revenue base across multiple continents.
Leadership & Governance
LivaNova is led by an executive team with experience in global medical technology, regulatory affairs, and operational execution. The leadership emphasizes patient-centered innovation, regulatory compliance, and long-term value creation, with governance structured to meet U.K. and U.S. public company standards.
Key executives include:
- Damien McDonald – Chief Executive Officer
- Dezso Molnar – Chief Financial Officer
- Jeffrey Trudel – President, Cardiopulmonary
- Dave Wise – President, Neuromodulation
- Gail Deady – Senior Vice President & Chief Human Resources Officer
The board and management team collectively guide corporate strategy, risk management, and capital allocation, with oversight informed by global regulatory and clinical requirements.